Pharmacoeconomic evaluation of docetaxel versus paclitaxel for the treatment of metastatic breast cancer;Evaluacion farmacoeconomica del docetaxel versus paclitaxel en el tratamiento del cancer de mama metastasico

Farmacia Hospitalaria

Volumn 24, Issue 4, 2000, Pages 226-240

  Ferriols Lisart, F ^a   Ferriols Lisart, R ^a   Magraner Gil, J ^a  

^a NONE   (Spain)

Author keywords

Cost effectiveness; Docetaxel; Metastatic breast cancer (MBC); Paclitaxel; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; NAVELBINE; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; HUMAN; MEDICAL INFORMATION; METASTASIS;

EID: 0033740834     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (131)

1. Docetaxel: A taxoid for the treatment of metastatic breast cancer
2. Breast cancer therapies in development. A review of their pharmacology and clinical potential
3. Role of chemotherapy for advanced colorectal cancer A new opportunities
4. Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy
5. The taxoids: Comparative clinical pharmacology and therapeutic potential
6. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
7. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer
8. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC
9. Docetaxel in patients with metastatic breast cancer. A phase II study of the National Cancer Institute of Canada. Clinical Trials Group
10. 2 as first line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer
11. Phase I study of docetaxel alternating with epirrubicin and cyclophosphamide in an escalated and acelerated schedule by the concomitant use of lenogastrim
12. Dose escalation study of docetaxel in combination with mitoxantrone as first line treatment in patients with metastatic breast cancer
13. Docetaxel (D) in combination with doxorubicin (Dx) as 1(st) line CT of metastatic breast cancer (MBC): A phase I dose finding study
14. Docetaxel combination with doxorrubicin or vinorelbine
15. Final results of a phase I dose finding and pharmacokinetic (PK) study of docetaxel in combination with vinorelbine in metastatic breast cancer
16. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer
17. Taxol and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer
18. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
19. Multi-center randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
20. A pilot study to evaluate paclitaxel (Taxol) as primary medical treatment for patients with inoperable stage III and IV breast carcinoma
21. Single agent paclitaxel as first line treatment of metastatic breast cancer: The British Experience
22. Phase II trial of paclitaxel (taxol) as first line chemotherapy for metastatic breast cancer
23. A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer
24. Taxol alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer
25. Efficacy of paclitaxel or doxorrubicin used as single agents in advanced breast cancer: A literature survey
26. Phase III trial of doxorrubicin (A) vs paclitaxel (T) vs doxorrubicin + paclitaxel (A + T) as first line therapy for metastatic breast cancer (MBC): An intergroup trial
27. A phase I/II study bi-weekly paclitaxel as first line treatment in metastatic breast cancer
28. 2 by 3 hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer
29. An ongoing European organization for research and treatment of cancer crossover trial comparing single agent paclitaxel and doxorrubicin as first and second line treatment of advanced breast cancer
30. Phase I/II study of 72 hour infusional paclitaxel and doxorrubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
31. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer
32. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity
33. Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
34. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer
35. A phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer
36. Interim Analysis of a phase II study of epirrubicin and paclitaxel as first line in patients with metastatic breast cancer
37. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer
38. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety
39. Phase I study of sequential adriamycin and taxol with neupogen support in advanced breast cancer
40. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer
41. A phase II trial of biweekly paclitaxel and cisplatin in patients with advanced breast carcinoma
42. Phase II study of paclitaxel plus carboplatin as first line chemotherapy for women with metastatic breast cancer (MBC): A North Central Cancer Treatment Group Trial
43. Paclitaxel and 5-fluorouracil in metastatic breast cancer
44. Phase I study of escalating doses of edetrexate in combination with paclitaxel in patients with metastatic breast cancer
45. Phase I trial of escalating dose of paclitaxel plus doxorrubicin and dexzeroxane in patients with advanced breast cancer
46. Sequential administration of doxorrubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer
47. Phase I/II study of paclitaxel and-vinorelbine in metastatic breast cancer
48. Dose finding study of paclitaxel and cyclophosphamide in women with advanceed breast cancer
49. Phase I/II clinical trial of epirrubicin and paclitaxel followed by granulocyte colony stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer
50. Prospective randomized trial of paclitaxel versus 5-fluorouracil/doxorrubicin/cyclophosphamide as induction therapy in patients with operable breast cancer
51. Phase I study of vinorelbine (Navelbine) and paclitaxel by simultaneous 3-hour infusion for untreated metastatic breast cancer
52. Paclitaxel and carboplatin as first line chemotherapy for advanced breast cancer
53. Combined doxorrubicin and paclitaxel in advanced breast cancer. Effective and cardiotoxic
54. Paclitaxel plus doxorrubicin in breast cancer. An Italian experience
55. A phase II trial of circadian time paclitaxel and cisplatin therapy in metastatic breast cancer
56. Paclitaxel 5-fluorouracil and folinic acid in metastatic breast cancer BRE-26, a phase II trial
57. Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South central hellenic Oncologu group
58. Paclitaxel and 5-fluoruracil in metastatic breast cancer: The US experience
59. A phase II trial of docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group
60. Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (taxotere) in the UK. UK Study Group
61. Docetaxel: Response in patients who have received at least two prior chemotherapy regimens for meastatic breast cancer
62. A phase II trial of docetaxel in patients with antracycline resistant metastatic breast cancer
63. Phase II trials of docetaxel in advanced anthracyclines resistant or antracecedione-resistant breast cancer
64. Phase II trial of docetaxel: A new highly effective antineoplasic agent in the management of patients with anthracycline resistant metastatic breast cancer
65. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer
66. Docetaxel (taxotere): An effective agent in the management of second line breast cancer
67. Phase II trial of single agent docetaxel in previously treated patients with advanced breast cancer
68. Efficacy of taxotere in advanced breast cancer patients not eligible for futher anthracycline
69. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: A preliminary report of the randomized phase III trial
70. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: Preliminary results
71. Activity and toxicity of docetaxel (taxotere) in women with previously treated metastatic breast cancer
72. Docetaxel: A new defence in the management of breast cancer
73. Salvage chemotherapy in antracyclinen pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Greek Breast Cancer Cooperative Group
74. Phase I study on docetaxel and ifosfamide in patients with advanced solid tumor
75. A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer
76. 3 Hour high dose taxol infusion in advancd breast cancer: An NSABP phase II study
77. Paclitaxel activity in anthracycline refractory breast cancer patients
78. High dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A european Cancer Center trial
79. Biweekly paclitaxel in the tretament of patients with metastatic breast cancer
80. Ninety six hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
81. Update: The MD Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma
82. Paclitaxel in metastatic breast cancer: A trial of two dose by a 3 hour infusion in patients with disease recurrence after prior therapy with anthracyclines
83. A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast
84. Paclitaxel in heavly pretreated breast cancer
85. Phase II study of semisynthetic paclitaxel in metastatic breast cancer
86. 2 by 3 hour infusion without G-CSF as a second line therapy in patients with metastatic breast cancer
87. Low activity of paclitaxel in patients with metastatic breast cancer resistant to anthracyclines
88. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer
89. Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer. Activity independent of prior anthracycline response
90. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center Trial
91. Paclitaxel administred by 1-hour infusion
92. Paclitaxel in doxorrubicin refractory or mitoxantrone refractory breast cancer: A phase I/II trial of 96 hour infusion
93. Paclitaxel in anthracycline treated breast cancer patients
94. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
95. Phase II trial of the use of taxol and ifosfamide in heavily pretreated patients with metastatic breast cancer
96. Phase II trial of taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer
97. Phase I/II trial of mitoxantrone and taxol in advanced breast cancer
98. Sequential taxol/platinum; pilot in metastatic breast cancer
99. Phase II study of sequential taxol and cisplatin for the treatment of metastatic breast cancer
100. Phase II study of biweekly cisplatin and paclitaxel in the treatment of metastatic breast cancer
101. Paclitaxel in combination with vinorelbine in pretreated advenced breast cancer patients
102. Intensified regimen with paclitaxel and vinorelbine in metastatic breast cancer (MBC): A phase II study
103. Paclitaxel plus vinorelbine in metastatic brast cancer patients with contraindications to receive anthracyclines
104. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgastrim for metastatic breast cancer: High complete response rate in a phase I-II study of doxorrubicin treated patients
105. Weekly paclitaxel cisplatin administration with G-CSF support in advanced breast cancer. A phase II study
106. A phase II trial of epirrubicin plus paclitaxel in metastatic breast cancer United Kingdom Coordinaty Committee for Cancer Research Breast Cancer
107. Weekly paclitaxel with epirrubicin as second line therapy of metastatic breast cancer: Results of a clinical phase II study
108. High rate of peripheral neuropathy may limit paclitaxel and cisplatin combination in women with advanced breast cancer
109. Paclitaxel and carboplatin with G-CSF support in advanced breast cancer resistant to anthracyclines
110. Paclitaxel complets with cyclophosphamide or cisplatin in metastatic breast cancer
111. Weekly high-dose 24 h infused 5-FU plus leucovorin (HD5-FD/LV) in combination with paclitaxel (P) and cisplatin (C) in the first line treatment of emtastatic breast cancer (MBC): Results of a phase II study
112. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide
113. Paclitaxel with mitoxantrone fluorouracil and high dose leucovorin in the treatment of metastatic breast cancer: A phase II trial
114. Taxol, folinic acid and fluorouracil as second line treatment for advanced breast cancer: A pilot study
115. Dose finding study of taxol and cyclophosphamide in advanced breast cancer
116. Preliminary report of a phase II study with paclitaxel and ifosfamide in patients with metastatic breast cancer
117. A phase II trial: Paclitaxel 5-fluorouracil and leucovorin in metastatic breast cancer
118. A preliminary report of an active salvage chemotherapy combining vinorelbine, paclitaxel and CDDP in anthracyclin resistant advanced breast cancer
119. Phase I trial of taxol, ifosphamide, cisplatin in patients with solid tumors
120. Metastatic breast cancer: Experience with the combination paclitaxel plus epirrubicin
121. Phase III trial of paclitaxel (P) and cisplatin (CDDP) in patients with advanced breast cancer refractory to antracycline (A) therapy
122. Paclitaxel by 3 h infusion and carboplatin in antracycline resistant advanced breast cancer. A phase II study conducted by th Helenic Cooperative Oncology Group
123. Paclitaxel combinations as front line and salvage chemotherapy regimens in advanced breast cancer
124. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients
125. Taxanos. Guia de prescripcion
126. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastasis breast cancer
127. Cost-utility analysis of taxane therapy
128. Infecciones en el paciente inmunocomprometido
129. Efficay and safety of docetaxel in clinical trials